Navigating Costs in NDMM: Key Considerations and What Influences Decision-Making

In ‘Navigating Costs in NDMM: Key Considerations and What Influences Decision-Making,' our panel of experts delve into the following critical questions:

1. Cost of therapy is an increasingly prominent factor in frontline treatment decision-making; how are you discussing cost with patients, and how does it influence your treatment approach?
2. From a pharmacy or managed care standpoint, how are institutions navigating the tension between clinical guidelines and formulary or payer restrictions in the frontline setting?

Led by the moderator, panelists discuss how high cost of treatment, including 20% co-insurance on expensive drugs, oral versus IV parity issues, and indirect expenses like transportation and hotels, significantly impacts both patients and providers. The panelists expressed that physicians must prepare patients for these financial requirements while guiding them to copayment assistance programs, and practices often involve financial counselors early to address lifelong expenses. At the institutional level, formulary decisions go beyond just drug prices to consider total resource utilization (e.g., monitoring, lab draws), with cost-effectiveness modeling and enterprise-wide consensus shaping frontline treatment choices.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'First Relapse in Multiple Myeloma: Balancing Options, Sequencing Decisions, and Patient-Centered Care,' panelists will continue their discussion on multiple myeloma and highlight how treatment selection at first relapse has evolved in an increasingly crowded second-line landscape, how clinicians are thinking about sequencing across lines of therapy, and whether the field needs clearer sequencing guidelines or whether the current framework provides valuable flexibility for individualized patient care.